drugset
drugset / Trial / NCT01633541

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

NCT01633541 ↗

Phase 2 Completed 55 enrolled University of Michigan Rogel Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate a new treatment approach for adults with advanced laryngeal cancer: induction chemotherapy with platinum and docetaxel plus AT-101. AT-101 is an investigational drug for the treatment of advanced cancer. It is hoped that the combination of this chemotherapy regimen will allow cancer patients to keep their voice box and to improve/maintain voice-related quality of life. The ultimate goal of this study is to prevent the surgery to remove subjects voice box.

Timeline

Start
2012-03
Primary completion
2021-11-06
Completion
2021-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AT-101 Small molecule 40 mg —
Background Carboplatin Small molecule 6 unknown —
Background Cisplatin Other / unclassified 100 mg/m2 —
Comparator Docetaxel Small molecule 75 mg/m2 —

Indications

larynx cancer